- Home
- CAPS vs TCRT Comparison
CAPS vs TCRT Comparison
Compare CAPS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPS
- TCRT
- Stock Information
- Founded
- CAPS 1987
- TCRT 1998
- Country
- CAPS United States
- TCRT United States
- Employees
- CAPS N/A
- TCRT N/A
- Industry
- CAPS
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- CAPS
- TCRT Health Care
- Exchange
- CAPS NYSE
- TCRT Nasdaq
- Market Cap
- CAPS 3.0M
- TCRT 2.5M
- IPO Year
- CAPS N/A
- TCRT N/A
- Fundamental
- Price
- CAPS $2.12
- TCRT $2.85
- Analyst Decision
- CAPS
- TCRT
- Analyst Count
- CAPS 0
- TCRT 0
- Target Price
- CAPS N/A
- TCRT N/A
- AVG Volume (30 Days)
- CAPS 998.6K
- TCRT 267.5K
- Earning Date
- CAPS 04-02-2025
- TCRT 05-14-2025
- Dividend Yield
- CAPS N/A
- TCRT N/A
- EPS Growth
- CAPS N/A
- TCRT N/A
- EPS
- CAPS N/A
- TCRT N/A
- Revenue
- CAPS $44,876,000.00
- TCRT $10,000.00
- Revenue This Year
- CAPS N/A
- TCRT N/A
- Revenue Next Year
- CAPS N/A
- TCRT N/A
- P/E Ratio
- CAPS N/A
- TCRT N/A
- Revenue Growth
- CAPS N/A
- TCRT 100.00
- 52 Week Low
- CAPS $1.72
- TCRT $1.31
- 52 Week High
- CAPS $16.18
- TCRT $18.50
- Technical
- Relative Strength Index (RSI)
- CAPS N/A
- TCRT 79.65
- Support Level
- CAPS N/A
- TCRT $1.31
- Resistance Level
- CAPS N/A
- TCRT $1.60
- Average True Range (ATR)
- CAPS 0.00
- TCRT 0.21
- MACD
- CAPS 0.00
- TCRT 0.09
- Stochastic Oscillator
- CAPS 0.00
- TCRT 80.00
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp operates through its wholly-owned subsidiary as a construction materials company, which distributes manufactured and natural stone cladding products, natural stone landscape products, and related goods for residential and commercial construction.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.